The Outcomes Research Consortium (stylized as OUTCOMES RESEARCH) is an international clinical research group that focuses on the perioperative period (during and after surgery), along with critical care and pain management. The Consortium's aim is to improve the quality of care for surgical, critical care, and chronic pain patients and to “Provide the evidence for evidence-based practice.” Members of the Consortium are especially interested in testing simple, low-risk, and inexpensive treatments that have the potential to markedly improve patients’ surgical experiences.The 25-year anniversary of the Consortium and its accomplishments were celebrated in an editorial in Anesthesiology. The editorial starts: Imagine a research group made up of more than 100 members working both independently and collaboratively across many countries having no legal standing, no bank account, and loosely organized, but devoted to the goal of improving health care through the understanding of the results of health care practices. Furthermore, imagine that members of this organization have published more than 900 full journal articles since its inception and publish a new full paper every 5 days. It may be hard to believe that such a unique organization exists, but it does. It is known as the Outcomes Research Consortium.
BACKGROUNDThe Biobeat wrist monitor (BB-613W; Biobeat Technologies, Petah-Tikva, Israel) and the Biobeat chest monitor (BB-613P; Biobeat Technologies) are wearable solutions for continuous noninvasive blood pressure monitoring.OBJECTIVE(S)We aimed to investigate the blood pressure measurement performance of the Biobeat wrist monitor and chest monitor after external calibration.DESIGNA prospective method comparison study.SETTINGUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.PATIENTSFifty high-risk patients recovering from noncardiac surgery in an advanced postanaesthesia care unit.MAIN OUTCOME MEASURESWe compared blood pressure measurements from the Biobeat wrist monitor (BPWRIST-ART) and the Biobeat chest monitor (BPCHEST-ART) with intra-arterial blood pressure measurements (BPART). In addition, we aimed to compare blood pressure measurements from the Biobeat wrist monitor (BPWRIST-OSCI) with those from an oscillometric upper-arm cuff (BPOSCI). We used Bland-Altman analysis, four-quadrant plot and error grid analysis for statistical analysis.RESULTSThe mean of the differences +/- standard deviation (95%-limits of agreement) between BPWRIST-ART and BPART was 3 +/- 11 mmHg (-19 to 25 mmHg) for mean blood pressure with a concordance rate to track 15-min blood pressure changes of 51%. The mean of the differences between BPCHEST-ART and BPART was 3 +/- 11 mmHg (-17 to 24 mmHg) for mean blood pressure with a concordance rate to track 15-min blood pressure changes of 61%. The mean of the differences between BPWRIST-OSCI and BPOSCI was 6 +/- 11 mmHg (-16 to 27 mmHg) for mean blood pressure with a concordance rate to track 15-min blood pressure changes of 49%.CONCLUSIONSBlood pressure measurements from the Biobeat wrist monitor and the Biobeat chest monitor did not show clinically acceptable agreement either with intra-arterial blood pressure measurements or with blood pressure measurements from an oscillometric upper-arm cuff in high-risk patients recovering from noncardiac surgery in an advanced postanaesthesia care unit.
Introduction The incidence of silent brain infarction (SBI) and perioperative neurocognitive disorders (PND) is higher in cardiac surgery. However, standard preventive strategies remain unknown due to limited evidence.Methods and analysis This multicentre, prospective, randomised controlled clinical trial with a 1-year follow-up includes patients undergoing elective cardiac surgery with cardiopulmonary bypass (CPB). 912 participants are randomly assigned 1:1 into either the intervention group with neuroprotective anaesthesia targets (mean arterial pressure 65–90 mm Hg, bispectral index 40–60, bilateral regional cerebral oxygen saturation ≥60%, arterial inflow temperature <37℃ and rewarming rate <0.5℃/min after exceeding 30℃ during CPB) or the control group maintained by anaesthetists according to routine care. The primary outcome is the 7-day incidence of new-onset SBI. The key secondary outcome is the 30-day incidence of PND. The secondary outcomes include the 5-day incidence of postoperative delirium, the 30-day incidence of new-onset overt stroke, the 1-year incidence of new-onset overt stroke, the 30-day incidence of transient ischaemic attack (TIA), the 1-year incidence of TIA, the 1-year incidence of PND, the 30-day and 1-year composite incidence of major adverse events (renal insufficiency, myocardial infarction, pulmonary embolism, seizure, all-cause mortality), length of stay (LOS) in intensive care unit, LOS in hospital and hospitalisation cost.Ethics and dissemination The trial was approved by the Institutional Review Board/Independent Ethics Committee of Fuwai Hospital (Approval No. 2024-2445) and all participating centres. We will disseminate the trial findings in peer-reviewed journals and present the results at national or international conferences.Trial registration number NCT07048002.
[This corrects the article DOI: 10.1016/j.cjco.2025.04.008.].
Unlabelled:Among 30,000 new wearable device users (11.6 million person-days), self-reported alcohol consumption significantly declined over 72 weeks, with the daily probability of drinking decreasing by 5.8 percentage points (P<.001) and reductions across age and biological sex.
